Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength?Zacks Investment Research • 12/18/24
Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn'sInvestopedia • 12/17/24
Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied DrugInvestors Business Daily • 12/17/24
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's DiseaseGlobeNewsWire • 12/17/24
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in JapanGlobeNewsWire • 12/05/24
Teva Pharmaceutical Industries Limited (TEVA) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call TranscriptSeeking Alpha • 12/05/24
Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE TrialGlobeNewsWire • 12/04/24
Teva Pharmaceutical Industries Limited (TEVA) Jefferies London Healthcare Conference (Transcript)Seeking Alpha • 11/19/24
TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance IncreaseZacks Investment Research • 11/07/24
Teva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Call TranscriptSeeking Alpha • 11/06/24
Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research • 11/06/24
Teva Pharmaceutical Flashes A Buy Signal On Upbeat Third-Quarter ReportInvestors Business Daily • 11/06/24
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPSGlobeNewsWire • 11/06/24